5 Sneak Peeks at the New Home of The James [Part 3]
Our vision to create a cancer-free world, one person, one discovery at a time, will become a reality only through the integration of research into clinical cancer care. These sneak peeks inside the new home of the The James Cancer Hospital and Solove Research Institute will demonstrate how discoveries in the lab translate to improved patient care for even our sickest patients.
The biorepository program at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) includes asking our patients to give universal consent to use their tissue and data to help us advance cancer research. Information and samples in the biorepository will provide clinicians and researchers with more insights into what causes cancer and, in turn, will lead to the development of targeted and more effective treatments.
As one of only four cancer centers in the nation funded by the National Cancer Institute to conduct both phase l and phase II clinical trials on novel anticancer drugs, and with a robust clinical trials program that involves nearly one in four patients diagnosed and treated at The James, we have an extraordinary opportunity to move cancer treatment forward. With more than 300 open clinical trials, the Clinical Trials Unit in the new home of The James will provide support for our physicians and researchers and offer hope for our patients and loved ones.
To discover, develop and deliver the most targeted treatments, teams of experts – physicians and scientists specializing in one type of cancer – must work together in the same space. In the new James, researchers and clinicians will work in closer proximity to each other than ever before, enabling them to more quickly translate discoveries to patient care. When researchers share lab discoveries with clinicians, and clinicians share patient responses to treatments with researchers, we get a step closer to a cancer-free world.
Precision Cancer Medicine
We know there is no routine cancer and that each person’s cancer is different. The days of diagnosing a cancer solely by its location and stage are ending, and that is where precision cancer medicine begins. With technologies for genomic sequencing, we can learn more about a particular cancer – not just where it is, but what is inside the tumor at the molecular and genetic level, and understand what is driving this cancer to develop and grow. That information leads to better, targeted therapy for our patients and, ultimately, to improved outcomes, faster responses, fewer side effects and more hope.
There are many reasons why a cancer patient may need critical care, such as respiratory distress, infection or complications from treatment. The cancer critical care units in the new James will combine the expertise of critical care intensivists, sub-specialized oncologists, pharmacists, critical care nurses, respiratory therapists and other specialists to provide the most comprehensive, multidisciplinary care to our sickest patients.